RxDoctor Payments Data

Hari Prasad Kunhi Veedu, MD

Neurology · Bakersfield, CANPI 1629237045

Payments from drug & device makers

$14,844in general payments, 2019–2025

Across 647 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Neuropace, Inc.$3K
  • UCB, Inc.$1K
  • Supernus Pharmaceuticals, Inc.$984
  • Neurelis, Inc.$956
  • Livanova USA, Inc.$648
  • plus $6K from 45 others

What the payments were for

  • Travel & lodging$1,58211%
  • Food & beverage$13,17689%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,844 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$152,849
Medicare patients
471
Services billed
2,572

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyvgartEfgartigimod Alfa-Fcab26$416,304
EpidiolexCannabidiol (Cbd)45$244,358
AptiomEslicarbazepine Acetate56$137,631
BriviactBrivaracetam50$125,818
XcopriCenobamate71$114,347
Aimovig AutoinjectorErenumab-Aooe50$35,029
NayzilamMidazolam16$34,874
Lacosamide116$23,423
ValtocoDiazepam24$22,540
Emgality PenGalcanezumab-Gnlm30$21,275
UbrelvyUbrogepant21$19,896
Diazepam13$16,388
Levetiracetam295$13,217
RytaryCarbidopa/Levodopa15$13,046
DepakoteDivalproex Sodium11$12,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart$354$416,30426 claims
UCB, Inc.Briviact, Nayzilam$1,031$160,69266 claims
Sunovion Pharmaceuticals Inc.Aptiom$191$137,63156 claims
SK Life Science, Inc.Xcopri$638$114,34771 claims
Neurelis, Inc.Valtoco$956$22,54024 claims
AbbVieUbrelvy$2,731$19,89621 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide, Mycophenolate Mofetil$68$17,73270 claims
Eisai Inc.Fycompa$97$12,77612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →